Olsalazine

Olsalazine Uses, Dosage, Side Effects, Food Interaction and all others data.

Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Mesalamine works as an anti-inflammatory agent in treating inflammatory diseases of the intestines.

Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine reduces the bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdominal pain. Olsalazine is thought to work like balsalazide, delivering mesalazine or 5-aminosalicylic acid past the small intestine to the large intestine to act on the site of disease.

Olsalazine
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Olsalazine
Availability	Prescription only
Generic	Olsalazine
Olsalazine Other Names	Olsalazine
Related Drugs	Entyvio, Humira, Zeposia, Colazal, prednisone, dexamethasone, methylprednisolone, hydrocortisone, hydrocortisone topical, budesonide
Weight	250mg
Type	Oral capsule
Formula	C₁₄H₁₀N₂O₆
Weight	Average: 302.239 Monoisotopic: 302.053886062
Protein binding	Olsalazine and olsalazine-S are more than 99% bound to plasma proteins. Mesalamine (5-ASA) is 74% bound to plasma proteins.
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Olsalazine is an anti-inflammatory agent used in the treatment of inflammatory bowel disease and ulcerative colitis.

For the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.

Olsalazine is also used to associated treatment for these conditions: Ulcerative Colitis

How Olsalazine works

Orally administered olsalazine is converted to mesalamine which is thought to be the therapeutically active agent in the treatment of ulcerative colitis. The mechanism of action of mesalamine (and sulfasalazine) is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid (AA) metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes (LTs) and hydroxyelcosatetraenoic acids (HETEs) is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin (PG) production in the colon.

Toxicity

Maximum single oral doses of 5g/kg in mice and rats and 2 g/kg in dogs were not lethal.

Food Interaction

Take with food.

Olsalazine Disease Interaction

Moderate: renal dysfunction

Elimination Route

After oral administration, olsalazine, has limited systemic bioavailability. 98-99% of the dose is converted to mesalamine (5-ASA) in the colon, which is absorbed slowly resulting in very high local concentrations in the colon.

Half Life

Olsalazine has an elimination half-life of 0.9 hours, however, olsalazine-S has a half-life of 7 days.

Elimination Route

Approximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S).The remaining 5-ASA is partially acetylated and is excreted in the feces.